CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2021
- Wall Street surges to all-time closing high on earnings, economic revival
- Was Intel's (INTC) Second Quarter a Speedbump or Inflection?
- Twitter (TWTR) Gains After Beating Q2 Estimates, Analysts Raise PTs as Brand Recovery Accelerates
- U.S. dollar on track for second week of gains; Fed meeting in focus
- Snap (SNAP) Surges 17% After Smashing Q2 Views Across the Board to Yield a Dozen Price Target Hikes
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
NEWARK, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be delivered during The International Liver Congress™ 2021 of the European Association for the Study of Liver (EASL) which will be held online June 23rd – 26th.
- A presentation1 will be made highlighting the efficacy, safety and tolerability of seladelpar in the important subset of patients having compensated liver cirrhosis due to PBC.
- A second clinical presentation2 examines the efficacy of seladelpar in PBC patients who were previously treated with obeticholic acid (Ocaliva) or fibrates.
- A third presentation3 will focus on adjudication of suspected drug-induced liver injury (DILI) in NASH patients using independent blinded review by a panel of pathologists and hepatologists.
- A preclinical presentation4 will highlight the effect of seladelpar and CB-0406 combination therapy on obesity, liver fibrosis and steatosis in an obese mouse model in NASH.
Dr. Dennis Kim, Chief Medical Officer of CymaBay Therapeutics, commented, “We are pleased to have the opportunity to present a wide range of abstracts at this year’s International Liver Congress™. The clinical results highlight the potential for seladelpar to offer PBC patients an efficacious and safe treatment option. We continue to advance clinical development activities with a focus on the seladelpar RESPONSE Phase 3 global pivotal study in PBC that is currently recruiting and enrolling patients.”
Presentations at The International Liver Congress™ 2021 include:
1“Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies” (Abstract #1809)Stuart C Gordon, Palak Trivedi, Christopher Bowlus, Michael Galambos, Aparna Goel, Aliya Gulamhusein, Cynthia Levy, Guy Neff, Carmen Stanca, Douglas Thorburn, Bruce Bacon, Brian Borg, Yvonne Doerffel, Lisa Forman, Bradley Freilich, Liana Gheorghe, María Saraí González, Stephen Harrison, Jonathan Huang, Sook-Hyang Jeong, Seung Up Kim, John Lake, Joseph Odin, Won Young Tak, Hillel Tobias, John M. Vierling, Ke Yang, Alexandra (Sasha) Steinberg, Yun-Jung Choi, Charles McWherter, Marlyn J. Mayo
2“Treatment with seladelpar in patients with primary biliary cholangitis (PBC) and prior experience with obeticholic acid (OCA) or fibrates” (Abstract #2120)Aliya Gulamhusein, Guy Neff, Aparna Goel, Marlyn J. Mayo, Carmen Stanca, Christopher Bowlus, Lisa Forman, Pietro Invernizzi, Frederik Nevens, Ehud Zigmond, Eli Zuckerman, Ke Yang, Yun-Jung Choi, Alexandra (Sasha) Steinberg, Charles McWherter, Kris V. Kowdley
3“An independent blinded review of suspected drug-induced liver injury (DILI) in nonalcoholic steatohepatitis (NASH) patients by a panel of pathologists and hepatologists: lessons learned from the seladelpar hepatoxicity review committee (SHRC)” (Abstract # 1504)Paul Watkins, David E Kleiner, Pierre Bedossa, Zack Goodman, Neil Kaplowitz, Willis Maddrey, John M. Vierling, Michael Charlton, Cynthia Guy, Elizabeth Brunt, Stephen Harrison, Edward Cable, Yun-Jung Choi, Sujal Shah, Klara Dickinson, Charles McWherter4“Effect of seladelpar and CB-0406 combination therapy on obesity, liver fibrosis and steatosis in a diet-induced obese (DIO) mouse model of biopsy-confirmed non-alcoholic steatohepatitis (NASH) with fibrosis” (Abstract #1797)Yun-Jung Choi, Jeffrey Stebbins, Ed Cable, Jiangao Song, Jeff Johnson, Charles McWherter
Congress attendees can visit CymaBay throughout the virtual meeting at the CymaBay microsite. A full list of presentations can be found on The International Liver Congress ™ 2021 website. The presentations will also be made available later this month on the CymaBay website.
About SeladelparSeladelpar is a potent, selective, orally active PPARδ agonist that has been in development for the treatment of the liver diseases primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For PBC, seladelpar has received an orphan designation from the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicine status from the EMA.
About CymaBayCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin.
Cautionary StatementsThe statements in this press release regarding the potential for seladelpar to treat NASH or PBC, the potential benefits to patients, CymaBay’s expectations and plans regarding its current and future clinical trials and CymaBay’s ability to fund current and planned clinical trials are forward looking statements that are subject to risks and uncertainties. Actual results and the timing of events regarding the further development of seladelpar could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of any of CymaBay's product development activities, including clinical trials; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of CymaBay's product candidates in the United States or worldwide; and the ability of CymaBay to obtain sufficient financing to complete development, regulatory approval and commercialization of its product candidates in the United States and worldwide or to potentially restart clinical trials. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.
For additional information about CymaBay visit www.cymabay.com.
Public Relations Contact:
Glenn SilverLazar-FINN Partners(973) 818-8198Glenn.email@example.com
Investor Relations Contact:
Hans VitzthumLifeSci Advisors, LLC(617) 430-7578Hans@LifeSciAdvisors.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Global Settlement in James Brown Estate Case
- New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
- Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Related EntitiesTwitter, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!